Musk reportedly said as much in a “Spaces” event on X (the social media website previously known as Twitter and now owned by Musk).
The company won a regulatory nod in May for a first-in-human implant, and in September it opened up recruitment for its clinical trial. Last month, Musk posted on X that the first patient in that trial received an implant.
However, questions have since arisen over the clinical trial.
Earlier this month, Nature reported that some neuroscientists have frustrations about the lack of detailed information and no confirmations that the study has begun besides social media posts from the controversial entrepreneur. A significant lack of transparency has particularly raised eyebrows within the neuroscience field. That adds to many questions surrounding Neuralink over the past few years, including concerns over animal welfare and hazardous material transport practices.
Updates on the trial continue to only come through Musk, who earlier this week said that the first patient to receive the Neuralink implant fully recovered and can control a computer mouse using their thoughts. Musk claimed that “progress is good and the patient seems to have made a full recovery with no ill effects that we are aware of.”
According to Reuters, the Neuralink aim is now to get the patient to achieve as many clicks of the mouse button as possible.
